公开(公告)号：US11642396B2

公开(公告)日：2023-05-09

申请号：US14913562

申请日：2014-08-21

申请人： AIM ImmunoTech Inc.

发明人： William A. Carter ,  David R. Strayer

IPC分类号： A61K49/00 ,  A61K39/145 ,  A61K38/21 ,  A61K31/713 ,  C12Q1/70

CPC分类号： A61K38/212 ,  A61K31/713 ,  C12Q1/701

摘要： This disclosures relates to methods of preventing or reducing antigenic drift, viral reassortment and symptoms of wild-type and mutant influenza viruses in a host animal by determining if a host animal has been exposed to or infected by an avian influenza virus, and administering to the exposed host animal α-interferon.

公开(公告)号：US20220380769A1

公开(公告)日：2022-12-01

申请号：US17773538

申请日：2021-01-25

申请人： AIM ImmunoTech Inc.

发明人： Thomas K. EQUELS ,  David R. STRAYER ,  Diane L. YOUNG

IPC分类号： C12N15/117 ,  A61K31/713 ,  A61K9/00 ,  A61K9/06 ,  A61K9/08 ,  A61K9/107 ,  A61K9/127 ,  A61K9/16 ,  A61K9/19

摘要： This disclosure relates to a method of treating, preventing, or reducing a symptom of a virus infection, including a SARS-CoV-2 infection, by administering an effective amount of tdsRNA optionally with an anti-viral agent, to a subject.

公开(公告)号：US20220356476A1

公开(公告)日：2022-11-10

申请号：US17621648

申请日：2020-07-02

申请人： AIM ImmunoTech Inc.

发明人： David R. STRAYER ,  Thomas K. EQUELS

IPC分类号： C12N15/117 ,  A61K38/21 ,  A61K31/713 ,  A61K39/12 ,  A61P31/14

摘要： Disclosed are methods and compositions for at least preventing, treating, inhibiting, or attenuating an Ebola virus infection of a subject. The methods comprise administering an effective amount of a composition as described herein to the subject thereby at least preventing, treating, inhibiting, or attenuating the Ebola virus infection of the subject. The compositions comprise a therapeutic double-stranded RNA (tdsRNA) and additional optional components such as an Ebola antigen.

公开(公告)号：US20220387475A1

公开(公告)日：2022-12-08

申请号：US17769986

申请日：2020-10-22

申请人： AIM ImmunoTech Inc.

发明人： Thomas K. EQUELS ,  David R. STRAYER

IPC分类号： A61K31/7105 ,  A61K35/17 ,  A61K9/00 ,  A61P15/00

摘要： Disclosed is a method for treating endometriosis, preventing endometriosis, or ameliorating a symptom of endometriosis in a subject comprising the step of administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising as an active ingredient a therapeutic dsRNA (tdsRNA).

公开(公告)号：US20220280547A1

公开(公告)日：2022-09-08

申请号：US17745723

申请日：2022-05-16

申请人： AIM ImmunoTech Inc.

发明人： Thomas K. EQUELS ,  David R. STRAYER ,  Diane L. YOUNG

IPC分类号： A61K31/713 ,  A61K9/00 ,  A61P31/14

摘要： This disclosure relates to compositions and methods for treating a subject previously infected with a virus and afflicted with post viral fatigue symptoms such as, for example, Long Covid. The compositions and methods comprise a therapeutically effective amount of a composition comprising therapeutic double-stranded RNA tdsRNA.

公开(公告)号：US20220062321A1

公开(公告)日：2022-03-03

申请号：US17413387

申请日：2019-11-25

申请人： AIM ImmunoTech Inc.

发明人： David R. STRAYER ,  Diane L. YOUNG ,  Thomas K. EQUELS

IPC分类号： A61K31/713 ,  A61K47/64 ,  A61K47/61 ,  A61P21/06

摘要： The present invention relates to methods for treating a subject with myalgic encephalomyelitis/chronic fatigue syndrome symptoms comprising administering a target subject a pharmaceutical composition comprising a therapeutic dsRNA (tdsRNA).

公开(公告)号：US20210196744A1

公开(公告)日：2021-07-01

申请号：US17179301

申请日：2021-02-18

申请人： AIM ImmunoTech Inc.

发明人： David R. STRAYER ,  Thomas K. EQUELS

IPC分类号： A61K31/713 ,  A61K38/21 ,  A61K39/395 ,  A61P35/00 ,  A61K9/00

摘要： One aspect of this disclosure is directed to a method for treating a cancer in a subject in need thereof by administering to the subject at least a first compound and a second compound together or separately. The first compound is an effective amount of a checkpoint inhibitor optionally with at least one pharmaceutically acceptable carrier. The second compound is an effective amount of an Anti-Tumor Immune Enhancer (ATIE) optionally with at least one pharmaceutically acceptable carrier. The compounds can be administered together or separately.

公开(公告)号：US12102649B2

公开(公告)日：2024-10-01

申请号：US17769986

申请日：2020-10-22

申请人： AIM ImmunoTech Inc.

发明人： Thomas K. Equels ,  David R. Strayer

IPC分类号： A61K31/7105 ,  A61K9/00 ,  A61K31/713 ,  A61K35/17 ,  A61P15/00

CPC分类号： A61K31/7105 ,  A61K9/0024 ,  A61K35/17 ,  A61P15/00 ,  A61K31/713

摘要： Disclosed is a method for treating endometriosis, preventing endometriosis, or ameliorating a symptom of endometriosis in a subject comprising the step of administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising as an active ingredient a therapeutic dsRNA (tdsRNA).

公开(公告)号：US11813279B2

公开(公告)日：2023-11-14

申请号：US16537442

申请日：2019-08-09

申请人： AIM IMMUNOTECH INC.

发明人： David R. Strayer ,  Thomas K. Equels

IPC分类号： A61K31/713 ,  A61K38/21 ,  A61K39/395 ,  A61P35/00 ,  A61K9/00 ,  A61K39/00

CPC分类号： A61K31/713 ,  A61K9/0019 ,  A61K38/212 ,  A61K39/3955 ,  A61P35/00 ,  A61K2039/505

摘要： One aspect of this disclosure is directed to a method for treating a cancer in a subject in need thereof by administering to the subject at least a first compound and a second compound together or separately. The first compound is an effective amount of a checkpoint inhibitor optionally with at least one pharmaceutically acceptable carrier. The second compound is an effective amount of an Anti-Tumor Immune Enhancer (ATIE) optionally with at least one pharmaceutically acceptable carrier. The compounds can be administered together or separately.

公开(公告)号：US20220096518A1

公开(公告)日：2022-03-31

申请号：US17416358

申请日：2019-12-20

申请人： AIM ImmunoTech Inc.

发明人： David R. STRAYER ,  Thomas K. EQUELS

IPC分类号： A61K31/713 ,  A61K47/64 ,  A61K38/21 ,  A61K39/395 ,  A61K31/7068 ,  A61K31/519 ,  A61K31/513 ,  A61K31/4745 ,  A61K31/282

摘要： One aspect of this disclosure is directed to a method for treating a cancer in a subject in need thereof by administering to the subject at least a first compound and a second compound in any order together or separately. The first compound is an effective amount of a checkpoint inhibitor optionally with at least one pharmaceutically acceptable carrier. The second compound is an effective amount of an Therapeutic Double Stranded RNA (tdsRNA) optionally with at least one pharmaceutically acceptable carrier. The compounds can be administered together or separately. Compositions for the practice of the method are also described.